{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:10:45Z","timestamp":1792782645719,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,10,6]],"date-time":"2016-10-06T00:00:00Z","timestamp":1475712000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Timcc","award":["317445"],"award-info":[{"award-number":["317445"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1007\/s00262-016-1909-3","type":"journal-article","created":{"date-parts":[[2016,10,6]],"date-time":"2016-10-06T11:25:27Z","timestamp":1475753127000},"page":"1-7","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation"],"prefix":"10.1007","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6687-1250","authenticated-orcid":false,"given":"Peter","family":"Ellmark","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara M.","family":"Mangsbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Furebring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Norl\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas H.","family":"T\u00f6tterman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,10,6]]},"reference":[{"key":"1909_CR1","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00262-014-1647-3","volume":"64","author":"PA Ascierto","year":"2015","unstructured":"Ascierto PA (2015) Immunotherapies and novel combinations: the focus of advances in the treatment of melanoma. Cancer Immunol Immunother 64:271\u2013274. doi: 10.1007\/s00262-014-1647-3","journal-title":"Cancer Immunol Immunother"},{"key":"1909_CR2","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1016\/j.molonc.2015.10.016","volume":"9","author":"L Hammerich","year":"2015","unstructured":"Hammerich L, Binder A, Brody JD (2015) In situ vaccination: cancer immunotherapy both personalized and off-the-shelf. Mol Oncol 9:1966\u20131981. doi: 10.1016\/j.molonc.2015.10.016","journal-title":"Mol Oncol"},{"key":"1909_CR3","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1080\/21645515.2015.1049779","volume":"11","author":"RH Pierce","year":"2015","unstructured":"Pierce RH, Campbell JS, Pai SI, Brody JD, Kohrt HE (2015) In-situ tumor vaccination: bringing the fight to the tumor. Hum Vaccin Immunother 11:1901\u20131909. doi: 10.1080\/21645515.2015.1049779","journal-title":"Hum Vaccin Immunother"},{"key":"1909_CR4","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/bs.ai.2015.12.001","volume":"130","author":"KK Wong","year":"2016","unstructured":"Wong KK, Li WA, Mooney DJ, Dranoff G (2016) Advances in therapeutic cancer vaccines. Adv Immunol 130:191\u2013249. doi: 10.1016\/bs.ai.2015.12.001","journal-title":"Adv Immunol"},{"key":"1909_CR5","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1084\/jem.20130579","volume":"210","author":"TR Simpson","year":"2013","unstructured":"Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F, Roddie C, Henry JY, Yagita H, Wolchok JD, Peggs KS, Ravetch JV, Allison JP, Quezada SA (2013) Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med 210:1695\u20131710. doi: 10.1084\/jem.20130579","journal-title":"J Exp Med"},{"key":"1909_CR6","doi-asserted-by":"publisher","first-page":"6140","DOI":"10.1073\/pnas.1417320112","volume":"112","author":"E Romano","year":"2015","unstructured":"Romano E, Kusio-Kobialka M, Foukas PG, Baumgaertner P, Meyer C, Ballabeni P, Michielin O, Weide B, Romero P, Speiser DE (2015) Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. Proc Natl Acad Sci 112:6140\u20136145. doi: 10.1073\/pnas.1417320112","journal-title":"Proc Natl Acad Sci"},{"key":"1909_CR7","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.cell.2015.03.030","volume":"161","author":"P Sharma","year":"2015","unstructured":"Sharma P, Allison JP (2015) Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 161:205\u2013214. doi: 10.1016\/j.cell.2015.03.030","journal-title":"Cell"},{"key":"1909_CR8","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1053\/j.seminoncol.2015.05.014","volume":"42","author":"MF Sanmamed","year":"2015","unstructured":"Sanmamed MF, Pastor F, Rodriguez A, Perez-Gracia JL, Rodriguez-Ruiz ME, Jure-Kunkel M, Melero I (2015) Agonists of co-stimulation in cancer immunotherapy directed against CD137, OX40, GITR, CD27, CD28, and ICOS. Semin Oncol 42:640\u2013655. doi: 10.1053\/j.seminoncol.2015.05.014","journal-title":"Semin Oncol"},{"key":"1909_CR9","doi-asserted-by":"publisher","first-page":"e1011484-1-3","DOI":"10.1080\/2162402X.2015.1011484","volume":"4","author":"P Ellmark","year":"2015","unstructured":"Ellmark P, Mangsbo SM, Furebring C, T\u00f6tterman TH, Norl\u00e9n P (2015) Kick-starting the cancer-immunity cycle by targeting CD40. Oncoimmunology 4:e1011484-1-3. doi: 10.1080\/2162402X.2015.1011484","journal-title":"Oncoimmunology"},{"key":"1909_CR10","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1158\/1078-0432.CCR-12-2064","volume":"19","author":"RH Vonderheide","year":"2013","unstructured":"Vonderheide RH, Glennie MJ (2013) Agonistic CD40 antibodies and cancer therapy. Clin Cancer Res 19:1035\u20131043. doi: 10.1158\/1078-0432.CCR-12-2064","journal-title":"Clin Cancer Res"},{"key":"1909_CR11","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1158\/2326-6066.CIR-13-0067","volume":"2","author":"LC Sandin","year":"2014","unstructured":"Sandin LC, Orlova A, Gustafsson E, Ellmark P, Tolmachev V, T\u00f6tterman TH, Mangsbo SM (2014) Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer. Cancer Immunol Res 2:80\u201390. doi: 10.1158\/2326-6066.CIR-13-0067","journal-title":"Cancer Immunol Res"},{"key":"1909_CR12","doi-asserted-by":"publisher","first-page":"5561","DOI":"10.1073\/pnas.082107699","volume":"99","author":"GJ Mierlo van","year":"2002","unstructured":"van Mierlo GJ, den Boer AT, Medema JP, van der Voort EI, Fransen MF, Offringa R, Melief CJ, Toes RE (2002) CD40 stimulation leads to effective therapy of CD40\u2212 tumors through induction of strong systemic cytotoxic T lymphocyte immunity. Proc Natl Acad Sci 99:5561\u20135566. doi: 10.1073\/pnas.082107699","journal-title":"Proc Natl Acad Sci"},{"key":"1909_CR13","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1158\/1078-0432.CCR-10-2888","volume":"17","author":"MF Fransen","year":"2011","unstructured":"Fransen MF, Sluijter M, Morreau H, Arens R, Melief CJ (2011) Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody. Clin Cancer Res 17:2270\u20132280. doi: 10.1158\/1078-0432.CCR-10-2888","journal-title":"Clin Cancer Res"},{"key":"1909_CR14","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1093\/intimm\/dxn104","volume":"20","author":"C Jackaman","year":"2008","unstructured":"Jackaman C, Lew AM, Zhan Y, Allan JE, Koloska B, Graham PT, Robinson BW, Nelson DJ (2008) Deliberately provoking local inflammation drives tumors to become their own protective vaccine site. Int Immunol 20:1467\u20131479. doi: 10.1093\/intimm\/dxn104","journal-title":"Int Immunol"},{"key":"1909_CR15","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1158\/1078-0432.CCR-14-0913","volume":"21","author":"SM Mangsbo","year":"2015","unstructured":"Mangsbo SM, Broos S, Fletcher E, Veitonm\u00e4ki N, Furebring C, Dahl\u00e9n E, Norl\u00e9n P, Lindstedt M, T\u00f6tterman TH, Ellmark P (2015) The human agonistic CD40 antibody ADC-1013 eradicates bladder tumors and generates T-cell-dependent tumor immunity. Clin Cancer Res 21:1115\u20131126. doi: 10.1158\/1078-0432.CCR-14-0913","journal-title":"Clin Cancer Res"},{"key":"1909_CR16","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1097\/CJI.0b013e3181acea69","volume":"32","author":"C Lindqvist","year":"2009","unstructured":"Lindqvist C, Sandin LC, Fransson M, Loskog A (2009) Local AdCD40L gene therapy is effective for disseminated murine experimental cancer by breaking T-cell tolerance and inducing tumor cell growth inhibition. J Immunother 32:785\u2013792. doi: 10.1097\/CJI.0b013e3181acea69","journal-title":"J Immunother"},{"key":"1909_CR17","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/S0022-5347(05)65928-9","volume":"166","author":"A Loskog","year":"2001","unstructured":"Loskog A, Bj\u00f6rkland A, Brown MP, Korsgren O, Malmstr\u00f6m PU, T\u00f6tterman TH (2001) Potent antitumor effects of CD154 transduced tumor cells in experimental bladder cancer. J Urol 166:1093\u20131097. doi: 10.1016\/S0022-5347(05)65928-9","journal-title":"J Urol"},{"key":"1909_CR18","doi-asserted-by":"publisher","first-page":"5929","DOI":"10.1158\/0008-5472.CAN-06-4296","volume":"67","author":"S Tuve","year":"2007","unstructured":"Tuve S, Chen BM, Liu Y, Cheng TL, Tour\u00e9 P, Sow PS, Feng Q, Kiviat N, Strauss R, Ni S, Li ZY, Roffler SR (2007) Lieber A (2007) Combination of tumor site-located CTL-associated antigen-4 blockade and systemic regulatory T-cell depletion induces tumor-destructive immune responses. Cancer Res 67:5929\u20135939. doi: 10.1158\/0008-5472.CAN-06-4296","journal-title":"Cancer Res"},{"key":"1909_CR19","doi-asserted-by":"publisher","first-page":"5381","DOI":"10.1158\/1078-0432.CCR-12-0781","volume":"19","author":"MF Fransen","year":"2013","unstructured":"Fransen MF, van der Sluis TC, Ossendorp F, Arens R, Melief CJ (2013) Controlled local delivery of CTLA-4 blocking antibody induces CD8+ T-cell-dependent tumor eradication and decreases risk of toxic side effects. Clin Cancer Res 19:5381\u20135389. doi: 10.1158\/1078-0432.CCR-12-0781","journal-title":"Clin Cancer Res"},{"key":"1909_CR20","doi-asserted-by":"publisher","first-page":"e27614-1-8","DOI":"10.4161\/onci.27614","volume":"3","author":"LC Sandin","year":"2014","unstructured":"Sandin LC, Eriksson F, Ellmark P, Loskog AS, T\u00f6tterman TH, Mangsbo SM (2014) Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo. Oncoimmunology 3:e27614-1-8. doi: 10.4161\/onci.27614","journal-title":"Oncoimmunology"},{"key":"1909_CR21","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","volume":"54","author":"JM Michot","year":"2016","unstructured":"Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, Berdelou A, Varga A, Bahleda R, Hollebecque A, Massard C, Fuerea A, Ribrag V, Gazzah A, Armand JP, Amellal N, Angevin E, Noel N, Boutros C, Mateus C, Robert C, Soria JC, Marabelle A, Lambotte O (2016) Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 54:139\u2013148. doi: 10.1016\/j.ejca.2015.11.016","journal-title":"Eur J Cancer"},{"key":"1909_CR22","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1172\/JCI64859","volume":"123","author":"A Marabelle","year":"2013","unstructured":"Marabelle A, Kohrt H, Sagiv-Barfi I, Ajami B, Axtell RC, Zhou G, Rajapaksa R, Green MR, Torchia J, Brody J, Luong R, Rosenblum MD, Steinman L, Levitsky HI, Tse V, Levy R (2013) Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J Clin Invest 123:2447\u20132463. doi: 10.1172\/JCI64859","journal-title":"J Clin Invest"},{"key":"1909_CR23","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1158\/2159-8290.CD-11-0314","volume":"2","author":"A Palaz\u00f3n","year":"2012","unstructured":"Palaz\u00f3n A, Mart\u00ednez-Forero I, Teijeira A, Morales-Kastresana A, Alfaro C, Sanmamed MF, Perez-Gracia JL, Pe\u00f1uelas I, Herv\u00e1s-Stubbs S, Rouzaut A, de Land\u00e1zuri MO, Jure-Kunkel M, Aragon\u00e9s J, Melero I (2012) The HIF-1\u03b1 hypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy. Cancer Discov 2:608\u2013623. doi: 10.1158\/2159-8290.CD-11-0314","journal-title":"Cancer Discov"},{"key":"1909_CR24","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1182\/blood-2011-05-355222","volume":"119","author":"YH Kim","year":"2012","unstructured":"Kim YH, Gratzinger D, Harrison C, Brody JD, Czerwinski DK, Ai WZ, Morales A, Abdulla F, Xing L, Navi D, Tibshirani RJ, Advani RH, Lingala B, Shah S, Hoppe RT, Levy R (2012) In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1\/2 study. Blood 119:355\u2013363. doi: 10.1182\/blood-2011-05-355222","journal-title":"Blood"},{"key":"1909_CR25","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1182\/blood-2010-06-288456","volume":"117","author":"MJ Goldstein","year":"2011","unstructured":"Goldstein MJ, Varghese B, Brody JD, Rajapaksa R, Kohrt H, Czerwinski DK, Levy S, Levy RA (2011) CpG-loaded tumor cell vaccine induces antitumor CD4+ T cells that are effective in adoptive therapy for large and established tumors. Blood 117:118\u2013127. doi: 10.1182\/blood-2010-06-288456","journal-title":"Blood"},{"key":"1909_CR26","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1158\/1078-0432.CCR-10-0385","volume":"16","author":"PU Malmstr\u00f6m","year":"2010","unstructured":"Malmstr\u00f6m PU, Loskog AS, Lindqvist CA, Mangsbo SM, Fransson M, Wanders A, G\u00e5rdmark T, T\u00f6tterman TH (2010) AdCD40L immunogene therapy for bladder carcinoma\u2014the first phase I\/IIa trial. Clin Cancer Res 16:3279\u20133287. doi: 10.1158\/1078-0432.CCR-10-0385","journal-title":"Clin Cancer Res"},{"key":"1909_CR27","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1097\/CJI.0b013e31816a812d","volume":"31","author":"H Euler von","year":"2008","unstructured":"von Euler H, Sadeghi A, Carlsson B, Rivera P, Loskog A, Segall T, Korsgren O, T\u00f6tterman TH (2008) Efficient adenovector CD40 ligand immunotherapy of canine malignant melanoma. J Immunother 31:377\u2013384. doi: 10.1097\/CJI.0b013e31816a812d","journal-title":"J Immunother"},{"key":"1909_CR28","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1097\/CJI.0b013e31829d8a1b","volume":"36","author":"S Westberg","year":"2013","unstructured":"Westberg S, Sadeghi A, Svensson E, Segall T, Dimopoulou M, Korsgren O, Hemminki A, Loskog AS, T\u00f6tterman TH, von Euler H (2013) Treatment efficacy and immune stimulation by AdCD40L gene therapy of spontaneous canine malignant melanoma. J Immunother 36:350\u2013358. doi: 10.1097\/CJI.0b013e31829d8a1b","journal-title":"J Immunother"},{"key":"1909_CR29","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1038\/bjc.2016.42","volume":"114","author":"A Loskog","year":"2016","unstructured":"Loskog A, Maleka A, Mangsbo S, Svensson E, Lundberg C, Nilsson A, Krause J, Agnarsd\u00f3ttir M, Sundin A, Ahlstr\u00f6m H, T\u00f6tterman TH, Ullenhag G (2016) Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients. Br J Cancer 114:872\u2013880. doi: 10.1038\/bjc.2016.42","journal-title":"Br J Cancer"},{"key":"1909_CR30","doi-asserted-by":"publisher","first-page":"862925","DOI":"10.1155\/2014\/862925","volume":"2014","author":"A Hemminki","year":"2014","unstructured":"Hemminki A (2014) Oncolytic immunotherapy: where are we clinically? Scientifica (Cairo) 2014:862925. doi: 10.1155\/2014\/862925","journal-title":"Scientifica (Cairo)"},{"key":"1909_CR31","doi-asserted-by":"publisher","first-page":"6230","DOI":"10.1016\/j.biomaterials.2012.05.011","volume":"33","author":"S Broos","year":"2012","unstructured":"Broos S, Sandin LC, Apel J, T\u00f6tterman TH, Akagi T, Akashi M, Borrebaeck CA, Ellmark P, Lindstedt M (2012) Synergistic augmentation of CD40-mediated activation of antigen-presenting cells by amphiphilic poly(\u03b3-glutamic acid) nanoparticles. Biomaterials 33:6230\u20136239. doi: 10.1016\/j.biomaterials.2012.05.011","journal-title":"Biomaterials"},{"key":"1909_CR32","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1016\/j.vaccine.2014.01.056","volume":"32","author":"MF Fransen","year":"2014","unstructured":"Fransen MF, Cordfunke RA, Sluijter M, van Steenbergen MJ, Drijfhout JW, Ossendorp F, Hennink WE, Melief CJ (2014) Effectiveness of slow-release systems in CD40 agonistic antibody immunotherapy of cancer. Vaccine 32:1654\u20131660. doi: 10.1016\/j.vaccine.2014.01.056","journal-title":"Vaccine"},{"key":"1909_CR33","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1126\/science.aaf1490","volume":"351","author":"N McGranahan","year":"2016","unstructured":"McGranahan N, Furness AJ, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, Jamal-Hanjani M, Wilson GA, Birkbak NJ, Hiley CT, Watkins TB, Shafi S, Murugaesu N, Mitter R, Akarca AU, Linares J, Marafioti T, Henry JY, Van Allen EM, Miao D, Schilling B, Schadendorf D, Garraway LA, Makarov V, Rizvi NA, Snyder A, Hellmann MD, Merghoub T, Wolchok JD, Shukla SA, Wu CJ, Peggs KS, Chan TA, Hadrup SR, Quezada SA, Swanton C (2016) Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351:1463\u20131469. doi: 10.1126\/science.aaf1490","journal-title":"Science"},{"key":"1909_CR34","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1111\/imr.12391","volume":"270","author":"JD Kiefer","year":"2016","unstructured":"Kiefer JD, Neri D (2016) Immunocytokines and bispecific antibodies: two complementary strategies for the selective activation of immune cells at the tumor site. Immunol Rev 270:178\u2013192. doi: 10.1111\/imr.12391","journal-title":"Immunol Rev"},{"key":"1909_CR35","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.coi.2016.03.006","volume":"40","author":"D Neri","year":"2016","unstructured":"Neri D, Sondel PM (2016) Immunocytokines for cancer treatment: past, present and future. Curr Opin Immunol 40:96\u2013102. doi: 10.1016\/j.coi.2016.03.006","journal-title":"Curr Opin Immunol"},{"key":"1909_CR36","doi-asserted-by":"publisher","first-page":"149","DOI":"10.3390\/antib1020149","volume":"1","author":"PM Sondel","year":"2012","unstructured":"Sondel PM, Gillies SD (2012) Current and potential uses of immunocytokines as cancer immunotherapy. Antibodies 1:149\u2013171. doi: 10.3390\/antib1020149","journal-title":"Antibodies"},{"key":"1909_CR37","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s00262-014-1621-0","volume":"64","author":"R Danielli","year":"2015","unstructured":"Danielli R, Patuzzo R, Ruffini PA, Maurichi A, Giovannoni L, Elia G, Neri D, Santinami M (2015) Armed antibodies for cancer treatment: a promising tool in a changing era. Cancer Immunol Immunother 64:113\u2013121. doi: 10.1007\/s00262-014-1621-0","journal-title":"Cancer Immunol Immunother"},{"key":"1909_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-015-0221-y","volume":"34","author":"GJ Yoshida","year":"2015","unstructured":"Yoshida GJ (2015) Metabolic reprogramming: the emerging concept and associated therapeutic strategies. J Exp Clin Cancer Res 34:1\u201310. doi: 10.1186\/s13046-015-0221-y","journal-title":"J Exp Clin Cancer Res"},{"key":"1909_CR39","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0969-2126(98)00008-2","volume":"6","author":"DE Vaughn","year":"1998","unstructured":"Vaughn DE, Bjorkman PJ (1998) Structural basis of pH-dependent antibody binding by the neonatal Fc receptor. Structure\u00a06:63\u201373","journal-title":"Structure"},{"key":"1909_CR40","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1517\/14712598.2014.920814","volume":"14","author":"KR Polu","year":"2014","unstructured":"Polu KR, Lowman HB (2014) Probody therapeutics for targeting antibodies to diseased tissue. Expert Opin Biol Ther 14:1049\u20131053. doi: 10.1517\/14712598.2014.920814","journal-title":"Expert Opin Biol Ther"},{"key":"1909_CR41","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s40265-015-0356-3","volume":"75","author":"M Sanford","year":"2015","unstructured":"Sanford M (2015) Blinatumomab: first global approval. Drugs 75:321\u2013327. doi: 10.1007\/s40265-015-0356-3","journal-title":"Drugs"},{"key":"1909_CR42","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.coi.2016.02.006","volume":"40","author":"EA Zhukovsky","year":"2016","unstructured":"Zhukovsky EA, Morse RJ, Maus MV (2016) Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection. Curr Opin Immunol 40:24\u201335. doi: 10.1016\/j.coi.2016.02.006","journal-title":"Curr Opin Immunol"},{"key":"1909_CR43","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.ccr.2010.11.012","volume":"19","author":"NS Wilson","year":"2011","unstructured":"Wilson NS, Yang B, Yang A, Loeser S, Marsters S, Lawrence D, Li Y, Pitti R, Totpal K, Yee S, Ross S, Vernes JM, Lu Y, Adams C, Offringa R, Kelley B, Hymowitz S, Daniel D, Meng G, Ashkenazi A (2011) An Fc\u03b3 receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. Cancer Cell 19:101\u2013113. doi: 10.1016\/j.ccr.2010.11.012","journal-title":"Cancer Cell"},{"key":"1909_CR44","doi-asserted-by":"publisher","first-page":"19501","DOI":"10.1073\/pnas.1319502110","volume":"110","author":"F Li","year":"2013","unstructured":"Li F, Ravetch JV (2013) Antitumor activities of agonistic anti-TNFR antibodies require differential Fc\u03b3RIIB coengagement in vivo. Proc Natl Acad Sci 110:19501\u201319506. doi: 10.1073\/pnas.1319502110","journal-title":"Proc Natl Acad Sci"},{"key":"1909_CR45","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.4049\/jimmunol.1101135","volume":"187","author":"AL White","year":"2011","unstructured":"White AL, Chan HT, Roghanian A, French RR, Mockridge CI, Tutt AL, Dixon SV, Ajona D, Verbeek JS, Al-Shamkhani A, Cragg MS, Beers SA, Glennie MJ (2011) Interaction with Fc\u03b3RIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody. J Immunol 187:1754\u20131763. doi: 10.4049\/jimmunol.1101135","journal-title":"J Immunol"},{"key":"1909_CR46","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/8426","volume":"5","author":"RR French","year":"1999","unstructured":"French RR, Chan HT, Tutt AL, Glennie MJ (1999) CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat Med 5:548\u2013553. doi: 10.1038\/8426","journal-title":"Nat Med"},{"key":"1909_CR47","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nm0697-682","volume":"3","author":"I Melero","year":"1997","unstructured":"Melero I, Shuford WW, Newby SA, Aruffo A, Ledbetter JA, Hellstr\u00f6m KE, Mittler RS, Chen L (1997) Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med 3:682\u2013685","journal-title":"Nat Med"},{"key":"1909_CR48","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1097\/CJI.0b013e31818353e9","volume":"31","author":"D M\u00fcller","year":"2008","unstructured":"M\u00fcller D, Frey K, Kontermann RE (2008) A novel antibody-4-1BBL fusion protein for targeted costimulation in cancer immunotherapy. J Immunother 31:714\u2013722. doi: 10.1097\/CJI.0b013e31818353e9","journal-title":"J Immunother"},{"key":"1909_CR49","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1097\/CJI.0b013e3182594387","volume":"35","author":"N Hornig","year":"2012","unstructured":"Hornig N, Kermer V, Frey K, Diebolder P, Kontermann RE, M\u00fcller D (2012) Combination of a bispecific antibody and costimulatory antibody-ligand fusion proteins for targeted cancer immunotherapy. J Immunother 35:418\u2013429. doi: 10.1097\/CJI.0b013e3182594387","journal-title":"J Immunother"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-016-1909-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-016-1909-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-016-1909-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T20:30:15Z","timestamp":1498336215000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-016-1909-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,6]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["1909"],"URL":"https:\/\/doi.org\/10.1007\/s00262-016-1909-3","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,6]]}}}